LYDIA FENNESSY: Open Payments
NPI 1285212803 · KITTANNING, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,749 in 80 payments from 30 companies in 2025. Trend: 2023 $1,268 · 2024 $1,786 · 2025 $1,749
Food & beverage: $1,663Education: $86
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $182 |
| Incyte Corporation | 8 | $174 |
| Merck Sharp & Dohme LLC | 5 | $127 |
| Ipsen Biopharmaceuticals, Inc | 3 | $120 |
| E.R. Squibb & Sons, L.L.C. | 5 | $111 |
| AstraZeneca Pharmaceuticals LP | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Genentech USA, Inc. | 3 | $78 |
| Geron Corporation | 3 | $74 |
| ABBVIE INC. | 3 | $66 |
Products named: KEYTRUDA, JAKAFI, SCEMBLIX, RYTELO, VENCLEXTA, OPDIVO, PLUVICTO, Polivy.
Industry payments across PA — which companies pay providers there.
